down arrow

Omeros Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6821431029
USD
11.03
1.6 (16.97%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.3711.03

52 Week

2.9513.60
Valuation
Technical
Day's Volume

CASH

411.1 k

Shareholding (Mar 2025)

FII

4.11%

Held by 33 FIIs

DII

81.0%

Held by 18 DIIs

Promoter

0.00%

How big is Omeros Corp.?

22-Jun-2025

As of Jun 18, Omeros Corp. has a market capitalization of 188.08 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -176.33 million over the last four quarters. The balance sheet as of Dec'24 shows shareholder's funds of -182.61 million and total assets of 277.08 million.

As of Jun 18, Omeros Corp. has a market capitalization of 188.08 million, categorizing it as a Micro Cap company.<BR><BR>As of the latest four quarters, Omeros Corp. reported net sales of 0.00 million and a net profit of -176.33 million.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of -182.61 million and total assets of 277.08 million.

Read More

What does Omeros Corp. do?

22-Jun-2025

Omeros Corporation is a biopharmaceutical company focused on developing therapeutics for inflammation, complement-mediated diseases, and central nervous system disorders. It has a market cap of $188.08 million and reported a net profit loss of $38 million as of March 2025.

Overview:<BR>Omeros Corporation is a commercial-stage biopharmaceutical company engaged in discovering, developing, and commercializing therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -38 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 188.08 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.64<BR>Return on Equity: 82.58%<BR>Price to Book: -0.88<BR><BR>Contact Details:<BR>Address: 201 Elliott Ave W, SEATTLE WA: 98119-4240<BR>Tel: 1 206 6765000<BR>Website: http://www.omeros.com

Read More

Who are in the management team of Omeros Corp.?

22-Jun-2025

As of March 2022, Omeros Corp.'s management team includes Dr. Gregory Demopulos as Chairman, President, and CEO, with Mr. Thomas Cable as Lead Independent Director and several Independent Directors: Dr. Peter Demopulos, Mr. Ray Aspiri, Dr. Thomas Bumol, and Mr. Arnold Hanish.

As of March 2022, the management team of Omeros Corp. includes Dr. Gregory Demopulos, who serves as the Chairman of the Board, President, and Chief Executive Officer. The board also features Mr. Thomas Cable as the Lead Independent Director, along with Dr. Peter Demopulos, Mr. Ray Aspiri, Dr. Thomas Bumol, and Mr. Arnold Hanish, all serving as Independent Directors.

Read More

Is Omeros Corp. overvalued or undervalued?

25-Jun-2025

As of November 9, 2022, Omeros Corp. is overvalued with a negative Price to Book Value of -1.03 and a troubling ROCE of -120.45%, significantly lagging behind peers like Rigel Pharmaceuticals, and has seen a year-to-date stock decline of 67.71%.

As of 9 November 2022, Omeros Corp. moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently overvalued, as evidenced by its negative Price to Book Value of -1.03 and an EV to EBIT ratio of -3.46, which highlight its financial struggles. Additionally, the Return on Capital Employed (ROCE) stands at a troubling -120.45%, further underscoring the company's challenges in generating returns.<BR><BR>In comparison to its peers, Omeros Corp. significantly lags behind Rigel Pharmaceuticals, which has a P/E ratio of 9.21 and an EV to EBITDA of 7.02, indicating a much healthier valuation. Other peers like Astria Therapeutics and Merrimack Pharmaceuticals also show negative metrics, but none approach the extreme negative ratios seen with Omeros. The company's recent stock performance, with a year-to-date decline of 67.71% compared to a modest 2.44% gain in the S&P 500, reinforces the notion that Omeros is not only struggling but also overvalued in the current market context.

Read More

Is Omeros Corp. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Omeros Corp. is in a mildly bearish trend, with daily moving averages and weekly RSI indicating bearish momentum, while year-to-date performance shows a significant underperformance of -56.88% compared to the S&P 500's 12.22%.

As of 25 August 2025, the technical trend for Omeros Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD and KST are mildly bullish, the overall indicators suggest a lack of strength in the bullish direction. In terms of performance, Omeros has underperformed the S&P 500 significantly year-to-date, with a return of -56.88% compared to the S&P's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 287 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.50

stock-summary
Return on Equity

62.25%

stock-summary
Price to Book

-1.25

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-26 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
163.88%
0%
163.88%
6 Months
251.27%
0%
251.27%
1 Year
-0.27%
0%
-0.27%
2 Years
394.62%
0%
394.62%
3 Years
438.05%
0%
438.05%
4 Years
60.55%
0%
60.55%
5 Years
-22.65%
0%
-22.65%

Omeros Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Omeros Corp. technically bullish or bearish?

As of 25 August 2025, the technical trend for Omeros Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD and KST are mildly bullish, the overall indicators suggest a lack of strength in the bullish direction. In terms of performance, Omeros has underperformed the S&P 500 significantly year-to-date, with a return of -56.88% compared to the S&P's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-17.00%
EBIT to Interest (avg)
-6.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.64
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
51.35%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.03
EV to EBIT
-3.46
EV to EBITDA
-3.48
EV to Capital Employed
4.17
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-120.45%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 32 Schemes (14.89%)

Foreign Institutions

Held by 33 Foreign Institutions (4.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 31.12% vs -3.01% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-32.20",
          "val2": "-34.70",
          "chgp": "7.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "3.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.90",
          "val2": "-37.60",
          "chgp": "31.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.40% vs 3.90% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-168.30",
          "val2": "-163.60",
          "chgp": "-2.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "24.70",
          "val2": "30.80",
          "chgp": "-19.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "4.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-182.60",
          "val2": "-174.90",
          "chgp": "-4.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-32.20
-34.70
7.20%
Interest
0.00
3.70
-100.00%
Exceptional Items
5.20
0.00
Consolidate Net Profit
-25.90
-37.60
31.12%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 31.12% vs -3.01% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-168.30
-163.60
-2.87%
Interest
24.70
30.80
-19.81%
Exceptional Items
0.00
4.10
-100.00%
Consolidate Net Profit
-182.60
-174.90
-4.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4.40% vs 3.90% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Omeros Corp. stock-summary
stock-summary
Omeros Corp.
Pharmaceuticals & Biotechnology
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
Company Coordinates stock-summary
Company Details
201 Elliott Ave W , SEATTLE WA : 98119-4240
stock-summary
Tel: 1 206 6765000
stock-summary
http://www.omeros.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."